ACE2 News and Research

RSS

Study shows the SARS-CoV-2 accessory protein ORF7a inhibits HLA-I surface expression levels in human cells

Researchers identified a single viral gene product, the accessory factor ORF7a, facilitating SARS-CoV-2 immune evasion by downregulating the surface expression of MHC class I molecules.

1 Jun 2022

The pineapple-derived jacalin-related lectin as a potential anti-SARS-CoV-2 agent

Scientists demonstrated that the pineapple-derived jacalin-related lectin (AcmJRL/AnLec) could be an anti-SARS-CoV-2 agent.

31 May 2022

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Researchers assessed the neutralizing activity against SARS-CoV-2 Omicron variant after tixagevimab plus cilgavimab (T+C) administration.

30 May 2022

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Researchers explored the virological profiles of novel SARS-CoV-2 Omicron variants.

30 May 2022

Scientists determine trajectory and pathophysiology of post-COVID-19 syndrome

A new study utilizes multisystem imaging, along with biomarker analysis, to better understand the pathogenesis of COVID-19.

30 May 2022

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

Researchers compared the polymer-nanoparticle hydrogel system and standard routes of delivery of broadly neutralizing antibodies against SARS-CoV-2 in a mouse model.

27 May 2022

Cell membrane-bound enzyme is essential for SARS-CoV-2 infectivity, study shows

The membrane-bound form of angiotensin converting enzyme 2 (ACE2) is essential for enabling infection with SARS-CoV-2, the virus that causes COVID-19, according to a study published in the journal Cell.

26 May 2022

Researchers report novel interactions between the SARS-CoV-2 S protein and estrogen receptor alpha

Researchers profiled the binding sites of the entire SARS-CoV-2 spike protein sequence.

26 May 2022

SARS-CoV-2 variants BA.4 and BA.5 show substantial immune escape compared with BA.1 and BA.2

In a recent study posted to the bioRxiv* pre-print server, researchers characterized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron’s new sub-lineages, BA.4, BA.5, and BA.3.

26 May 2022

A 6.4 million genome analysis predicts dominant SARS-CoV-2 variants

In this new study in the journal Science, researchers have developed a hierarchical Bayesian regression model, named, PyR0, which can analyze the complete set of publicly available SARS-CoV-2 genomes.

26 May 2022

Study illustrates risk of Omicron infection in fully vaccinated individuals

Scientists studied SARS-CoV-2 humoral responses in a healthy young person who was infected by the Omicron BA.1.15 after receiving booster vaccination.

25 May 2022

Computational modeling fine tunes RBD-1C aptamer against SARS-CoV-2 S protein

Researchers used the SARS-CoV-2 sequence against aptamers to perform the in silico selection of an aptamer against the SARS-CoV-2 S protein.

24 May 2022

Vaccinated individuals with SARS-CoV-2 infection develop virus-specific T cells inside their noses

In a recent study posted to the medRxiv* preprint server, investigators in Singapore showed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection elicited broadly specific virus-selective nasal resident CD8 and CD4 T cells.

24 May 2022

Omicron vaccine breakthrough infections induce potent cross-reactive antibodies

In a recent study published in the journal Cell, researchers demonstrated that antibodies generated due to breakthrough infection (BTI) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) new variant of concern (VOC) Omicron in vaccinated individuals could neutralize all VOCs.

24 May 2022

ATLAS assay reveals SARS-CoV-2 variant T-cell responses

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

A new study has focused on designing immunogens associated with the conserved region of the spike protein of SARS-CoV-2.

20 May 2022

ACE2 News and Research

Study shows the SARS-CoV-2 accessory protein ORF7a inhibits HLA-I surface expression levels in human cells

The pineapple-derived jacalin-related lectin as a potential anti-SARS-CoV-2 agent

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Scientists determine trajectory and pathophysiology of post-COVID-19 syndrome

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

Cell membrane-bound enzyme is essential for SARS-CoV-2 infectivity, study shows

Researchers report novel interactions between the SARS-CoV-2 S protein and estrogen receptor alpha

SARS-CoV-2 variants BA.4 and BA.5 show substantial immune escape compared with BA.1 and BA.2

A 6.4 million genome analysis predicts dominant SARS-CoV-2 variants

Study illustrates risk of Omicron infection in fully vaccinated individuals

Computational modeling fine tunes RBD-1C aptamer against SARS-CoV-2 S protein

Vaccinated individuals with SARS-CoV-2 infection develop virus-specific T cells inside their noses

Omicron vaccine breakthrough infections induce potent cross-reactive antibodies

ATLAS assay reveals SARS-CoV-2 variant T-cell responses

Study reports SARS-CoV-2 accessory proteins downregulate MHC-I expression using distinct mechanisms

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Can human coronaviruses infect the GI tract?

Exploring the possibility of whether surface ACE2 carried by extracellular vesicles can facilitate SARS-CoV-2 infection

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News